American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: American Psychiatric Association; 1994.
2.
BorrasL, EytanA, de TimaryP, ConstantEL, HugueletP, HermansC: Pulmonary thromboembolism associated with olanzapine and risperidone. J Emerg Med, 35:159–161, 2008.
3.
CavannaAE, TermineC: Tourette syndrome. Adv Exp Med Biol, 724:375–383, 2012.
4.
GriffinJH, EvattB, WidemanC, FernándezJA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood, 82:1989–1993, 1993.
5.
HäggS, SpigsetO: Antipsychotic-induced venous thromboembolism: A review of the evidence. CNS Drugs, 16:765–776, 2002.
6.
HäggS, TättingP, SpigsetO: Olanzapine and venous thromboembolism. Int Clin Psychopharmacol, 18:299–300, 2003.
7.
HamanakaS, KamijoY, NagaiT, KuriharaK, TanakaK, SomaK, MiyaokaH: Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J, 68:850–852, 2004.
8.
JafferAK: An overview of venous thromboembolism: impact, risks, and issues in prophylaxis. Cleve Clin J Med, 75 (Suppl 3):3–6, 2008.
9.
KamijoY, SomaK, NagaiT, KuriharaK, OhwadaT: Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J, 67:46–48, 2003.
10.
KogaM, NakayamaK: Body weight gain induced by a newer antipsychotic agent. Acta Psychiatr Scand, 112:75–76, 2005.
11.
KosterT, RosendaalFR, de RondeH, BriëtE, VandenbrouckeJP, BertinaRM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet, 342:1503–1506, 1993.
12.
LacutK, Le GalG, CouturaudF, CornilyG, LeroyerC, MottierD, OgerE: Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol, 21:643–650, 2007.
13.
MarchioriA, MosenaL, PrinsMH, PrandoniP: The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica, 92:1107–1114, 2007.
14.
MasopustJ, MalýR, VališM: Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci, 66:541–552, 2012.
15.
MittalM, KhanS: Starvation causes acute psychosis due to anterior thalamic infarction. South Med J, 103:701–703, 2010.
16.
RidkerPM, HennekensCH, LindpaintnerK, StampferMJ, EisenbergPR, MiletichJP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med, 332:912–917, 1995.
17.
RosendaalFR, KosterT, VandenbrouckeJP, ReitsmaPH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood, 85:1504–1508, 1995.
18.
SeemanMV: Secondary effects of antipsychotics: Women at greater risk than men. Schizophr Bull, 35:937–948, 2009.
19.
SingerHS: Current issues in Tourette Syndrome. Mov Disord, 15:1051–1063, 2000.
20.
SvenssonPJ, DahlbackB: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med, 330:517–522, 1994.
21.
Van NesteEG, VerbruggenV, LeysenM: Deep venous thrombosis and pulmonary embolism in psychiatric settings. Eur J Psychiatry, 23:19–30, 2009.
